DiscGenics, Inc., a biopharmaceutical business in the clinical phase, concentrated on creating regenerative cell-based therapies that relieve pain and restore function in patients with spine degenerative diseases, announced today the online publication of a study in The Spine Journal summarizing the results of preclinical testing of IDCT active ingredient discogenic cells, DiscGenics’ research cell therapy for disc degeneration.
The Spine Journal, the official journal of the North American Spine Society (NASS), is a peer-reviewed medical journal covering studies linked to spine and spine care. The Spine Journal is one of the top peer-reviewed journals in the field of orthopedics with a 5-year impact factor of 3.196.
The manuscript, entitled “In Vitro and In Vivo Evaluation of Discogenic Cells, An Investigational Cell Therapy for Disc Degeneration,” shows that Discogenic Cells intradiscal injection can be a viable treatment for human degenerative disorder (DDD), citing that the cells generate extracellular matrix that can reconstruct depleting tissue in degenerative disks and do not pose important safety issues.
Discogenic cells are biomedically engineered progenitor cells obtained from donated human intervertebral tissue to tackle the complicated environment of the degenerated disk uniquely. IDCT is a homologous, allogeneic, injectable disk cell therapy that uses Discogenic Cells to provide a non-surgical, possibly regenerative alternative for the treatment of mild to moderate DDD patients.
The aim of the presented research was to assess Discogenic Cells’ features, mode of action, and in vivo effectiveness and safety before human clinical testing. In vitro, discogenic cells produced from various adult human donors were assessed for surface marker expression profile, matrix deposition, and tumor potential. Then, Discogenic Cells were characterized in vitro by subcutaneous implantation and intradiscal injection of human Discogenic Cells in models of naked mouse and rabbit degeneration.